| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 1.9K | 11.7% | 15.9% |
| Total Income | 1.9K | 11.6% | 15.2% |
| Expenditure | 1.7K | 11.0% | 13.1% |
| PBT | 222.30 | 16.7% | 23.8% |
| Net Profit | 183.71 | 19.6% | 20.0% |
| OPM | 16.53% | 0.08pp | 12.07pp |
| NPM | 9.58% | 0.63pp | 0.43pp |
| EPS | 9.40 | 19.8% | 20.7% |
Alembic Pharmaceuticals Reports Q2 FY26 Revenue Growth of 16% and PAT Growth of 20% year ended 30\
04 Nov 2025 · 4 Nov 2025, 02:44 pm
Summary
Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter and half year ended 30° September 2025. The company's revenue from operations increased by 16% to Rs.1,910 Cr, EBITDA increased by 26% to Rs. 325 Cr, and EBITDA Margin was at 17% of revenue. The company reported Profit After Tax at Rs.185 Cr, up by 20%.
Key Highlights
- 1
India Branded Business delivered a 5% YoY growth, reaching 639 Cr in revenue for the quarter
- 2
US Generics grew by 21% to Rs. 566 Cr. for the quarter
- 3
Ex-US International Generics grew by 31% to Rs. 392 Cr. for the quarter
- 4
API business grew by 15% to Rs. 261 Cr. for the quarter
- 5
3 Launches in the US market during the quarter
- 6
6 ANDA approvals received during the quarter, 226 Cumulative ANDA approvals
Management Comments
Mr. Shaunak Amin
Our Q2 performance reflects continued momentum in our core businesses and the disciplined execution. We have strengthened our presence across key markets while maintaining a sharp focus on profitability and operational excellence, delivering an overall growth of 16% and pre-R&D EBITDA margin of 26%.
Informational and educational content only. Not investment advice.